Nanotechnologie in Lebensmitteln - DLR Online: Deutsche ...

29) Mauskop A, Altura BM: Role of magnesium
in the pathogenesis and treatment
of migraines. Clin Neurosci 5(1), 24–27
(1998).
30) Pfaffenrath V et al.: Magnesium in
the prophylaxis of migraine – a double-blind
placebo-controlled study.
Cephalalgia 16(6), 436–440 (1996).
31) Zehender M et al.: Antiarrhythmic effects
of increasing the daily intake of
magnesium and potassium in patients
with frequent ventricular arrhythmias.
Magnesium in Cardiac Arrhythmias
(MAGICA) Investigators. J Am Coll Cardiol
29(5), 1028–1034 (1997).
32) Kasaoka S et al.: Effect of intravenous
magnesium sulfate on cardiac arrhythmias
in critically ill patients with low
serum ionized magnesium. Jpn Circ J
60(11), 871–875 (1996).
33) Moran JL et al.: Parenteral magnesium
sulfate versus amiodarone in the
therapy of atrial tachyarrhythmias: a
prospective, randomized study. Crit
Care Med 23(11), 1816–1824 (1995).
34) Shechter M et al.: Oral magnesium
therapy improves endothelial function
in patients with coronary artery disease.
Circulation 102(19), 2353–1358 (2000).
35) Hwang DL, Yen CF, Nadler JL: Effect of
extracellular magnesium on platelet activation
and intracellular calcium mobilization.
Am J Hypertens 5(10), 700–
706 (1992).
36) Shechter M et al.: Oral magnesium supplementation
inhibits platelet-dependent
thrombosis in patients with coronary
artery disease. Am J Cardiol 84(2),
152–156 (1999).
37) Stepura OB, Martynow AI: Magnesium
orotate in severe congestive heart failure
(MACH). Int J Cardiol 124, 40–46
(2008).
38) Woods KL, Fletcher S: Long-term outcome
after intravenous magnesium sulphate
in suspected acute myocardial
infarction: the second Leicester Intravenous
Magnesium Intervention Trial
(LIMIT-2). Lancet 343(8901), 816–819
(1994).
39) ISIS-4 Collaborative: ISIS-4: a randomised
factorial trial assessing early
oral captopril, oral mononitrate, and
intravenous magnesium sulphate in
DLR | November/Dezember 2008 «
58,050 patients with suspected acute
myocardial infarction. ISIS-4 (Fourth International
Study of Infarct Survival).
Lancet 345(8951), 669–685 (1995).
40) Ziegelstein RC et al.: Magnesium use in
the treatment of acute myocardial infarction
in the United States (observations
from the Second National Registry
of Myocardial Infarction). Am J Cardiol
87(1), 7–10 (2001).
41) Stamler J, Caggiula AW, Grandits GA:
Relation of body mass and alcohol, nutrient,
fi ber, and caffeine intakes to
blood pressure in the special intervention
and usual care groups in the Multiple
Risk Factor Intervention Trial.
Am J Clin Nutr 65(1 Suppl), 338–365
(1997).
42) Nadler JL, Rude RK: Disorders of magnesium
metabolism. Endocrinol Metab
Clin North Am 24, 623–641 (1995).
43) Joffres MR, Reed DM, Yano K: Relationship
of magnesium intake and other
dietary factors to blood pressure: the
Honolulu heart study. Am J Clin Nutr
45(2), 469–475 (1987).
44) Peacock JM et al.: Relationship of serum
and dietary magnesium to incident
hypertension: the Atherosclerosis Risk
in Communities (ARIC) Study. Ann Epidemiol
9(3), 159–165 (1999).
45) Sasaki S et al.: Abnormal magnesium
status in patients with cardiovascular
diseases. Clin Sci (Lond) 98(2), 175–181
(2000).
46) Champagne CM: Magnesium in hypertension,
cardiovascular disease, metabolic
syndrome, and other conditions:
a review. Nutr Clin Pract 23(2), 142–
151 (2008).
47) Yokota K et al.: Clinical effi cacy of magnesium
supplementation in patients
with type 2 diabetes. J Am Coll Nutr
23(5), 506–509 (2004).
48) Fox C, Ramsoomair D, Carter C: Magnesium:
its proven and potential clinical
signifi cance. South Med J 94, 1195–
1201 (2001).
49) Cappuccio FP et al.: Lack of effect of
oral magnesium on high blood pressure:
a double blind study. BMJ 291,
235–238 (1985).
50) Henderson DG, Schierup J, Schodt T: Effect
of magnesium supplementation on
» Forschung und Entwicklung 31B
blood pressure and electrolyte concentration
in hypertensive patients receiving
long term diuretic treatment. BMJ
293, 664–665 (1986).
51) Ferrara LA et al.: Long-term magnesium
supplementation in essential hypertension.
Gen Cardiol 81, 25-33 (1992).
52) Touyz RM: Role of magnesium in the
pathogenesis of hypertension. Mol Aspects
Med 24(1–3), 107–136 (2003).
53) Sontia B, Touyz RM: Role of magnesium
in hypertension. Arch Biochem Biophys
458(1), 333–339 (2007).
54) Greenberg A: Diuretic complications.
Am J Med Sci 319(1), 10–24 (2000).
55) Singh RB et al.: Magnesium metabolism
in essential hypertension. Acta Cardiol
44(4), 313–322 (1989).
56) Ruml LA et al.: Effect of varying doses
of potassium-magnesium citrate on thiazide-induced
hypokalemia and magnesium
loss. Am J Ther 6(1), 45–50
(1999).
57) Odvina CV, Mason RP, Pak CY: Prevention
of thiazide-induced hypokalemia
without magnesium depletion by potassium-magnesium-citrate.
Am J Ther
13(2), 101–108 (2006).
58) Ruml LA, Pak CY: Effect of potassium
magnesium citrate on thiazide-induced
hypokalemia and magnesium loss. Am J
Kidney Dis 34(1), 107–113 (1999).
59) Greene MF: Magnesium sulfate for
preeclampsia. N Engl J Med 348(4),
275–276 (2003).
60) Isler CM, Martin JN: Preeclampsia:
pathophysiology and practice considerations
for the consulting nephrologist.
Semin Nephrol 22(1), 54–64
(2002).
61) Johnson JD, Hand WL, King-Thompson
NL: The role of divalent cations in interactions
between lymphokines and macrophages.
Cell Immunol 53(2), 236–245
(1980).
62) Rukshin V et al.: Comparative antithrombotic
effects of magnesium sulfate
and the platelet glycoprotein IIb/
IIIa inhibitors tirofi ban and eptifi batide
in a canine model of stent thrombosis.
Circulation 105(16), 1970–1975 (2002).
63) Altman D et al.: Magpie Trial Collaboration
Group: Do women with pre-eclampsia,
and their babies, benefi t from